Patient Education Webcast—Expert Perspectives on Incorporating BTK Inhibitors into the Treatment Plan for Patients with CLL: Helpful Information for Patients and their Caregivers.

August 20, 2020

Expert Perspectives on Incorporating BTK Inhibitors into the Treatment Plan for Patients with CLL: Helpful Information for Patients and their Caregivers

Archived Webinar from September 3

Through a collaboration between CLL Society, Plexus Communications, and the Association of VA Hematology/Oncology (AVAHO), we invite you to view the archived webinar with Parameswaran Venugopal, MD from Rush University Medical Center in Chicago, IL, moderated by Bruce Wright, a Patient Advisor and Patient Educator for the CLL Society. Bruce is a United States military veteran who speaks to some of the challenges that are specific to veterans seeking treatment, as well as how patients and caregivers can increase their knowledge about CLL and become more involved in their treatment decisions. This webinar provides CLL patients and caregivers with information on the clinical use of BTK inhibitors for the treatment of their CLL to equip patients with the appropriate knowledge to make informed decisions with their care providers.

Watch the archived webinar here!

About the author

Brad Hedrick

Chronic Lymphocytic Leukemia (CLL) Patients and Protection against COVID-19: Passive and Active Immunity, Monoclonal Antibodies and Vaccines
February 25, 2021

Trials Studying the Safety and Immune Response of Chronic Lymphocytic Leukemia (CLL) Patients Receiving the COVID-19 Vaccines
February 12, 2021

FDA approves lisocabtagene maraleucel (liso-cel or JCAR-017) a CAR-T cell therapy for relapsed or refractory large B-cell lymphoma
February 6, 2021

CLL Society Quoted by CNN: Are Covid-19 vaccines safe for cancer patients? Here is what cancer experts say by Lauren Kent, CNN
February 5, 2021

NCCN: Cancer and COVID-19 Vaccination
February 4, 2021

ERIC’s Official Statement: SARS-CoV-2 Vaccine in Patients with CLL
February 2, 2021